Effects of diphenylhydantoin and cholinergic agents on the neuronally isolated cerebral cortex.
D000818:Animals; D001285:Atropine / Q000494:pharmacology; D002415:Cats; D002540:Cerebral Cortex / Q000187:drug effects*; D004195:Disease Models, Animal; D004569:Electroencephalography; D004827:Epilepsy / Q000503:physiopathology; D004832:Epilepsy, Absence / Q000503:physiopathology; D004830:Epilepsy, Tonic-Clonic / Q000503:physiopathology; D005013:Ethosuximide / Q000037:antagonists & inhibitors / Q000494:pharmacology; D010277:Parasympathomimetics / Q000494:pharmacology*; D010672:Phenytoin / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D010830:Physostigmine / Q000494:pharmacology; D010862:Pilocarpine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D012601:Scopolamine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D012640:Seizures / Q000503:physiopathology / Q000517:prevention & control*; D009435:Synaptic Transmission; D014293:Trimethadione / Q000494:pharmacology
D010277:Parasympathomimetics; D010862:Pilocarpine; D005013:Ethosuximide; D010672:Phenytoin; D001285:Atropine; D010830:Physostigmine; D012601:Scopolamine; D014293:Trimethadione